Medial EarlySign has partnered with Geisinger and its Steele Institute for Health Innovation to develop new machine learning-based solutions for the identification of people at risk of chronic and high-burden diseases.
EarlySign develops artificial intelligence (AI) solutions aimed at detecting and preventing diseases early.
Go deeper with GlobalData
As part of the latest multi-year alliance, the company’s advanced software solution called LGI-Flag will be deployed for the detection of individuals at risk of significant lower GI disorders.
LGI-Flag is designed to analyse medical data such as changes in routine blood tests in order to identify patients who will benefit from further assessment.
Geisinger and EarlySign will leverage the technology for similar application in other acute and chronic diseases. Geisinger will contribute to the alliance via its innovation infrastructure, data assets and care teams.
Geisinger associate chief quality officer Keith Boell said: “EarlySign’s technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances.”
EarlySign’s LGI-Flag solution has been in use since 2015. Healthcare systems worldwide leverage LGI-Flag to identify patients at risk for lower GI disorders that are related to chronic occult bleeding.
Medial EarlySign co-founder and CEO Ori Geva said: “This is the first step of our ultimate goal: enabling healthcare systems to identify and connect with those high-risk patients and engage with them early enough via interventions that may prevent or delay disease progression.”
In May, EarlySign unveiled new predictive risk solutions called AlgoMarkers for the identification of patients at high risk for diabetes and downstream complications.
